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Delayed gastric emptying after esophagogastrectomy can pose a significant 
early postoperative problem. Because erythromycin, which stimulates the 
gastric antral and duodenal motilin receptor, has been shown to significantly 
increase gastric emptying in patients with diabetic gastroparesis, we decided to 
evaluate its effect on gastric emptying after esophagogastrectomy. Methods: 
Twenty-four patients (18 men and six women, age range 41 to 79 years, median 
66 years) were randomized to receive either erythromycin lactobionate (200 mg 
in 50 ml normal saline solution intravenously) (n = 13) or placebo (50 ml 
normal saline solution intravenously (n = 11) 11 days after esophagogastrec- 
tomy (with pyloric drainage procedure). After erythromycin or placebo had 
been infused over a 15-minute period, patients ingested a solid meal (scram- 
bled egg with bread) labeled with technetium 99m sulfur colloid (500 gCi) over 
approximately 15 minutes. Dynamic images of the stomach were then acquired 
over 90 minutes in the supine position by gamma imaging. Results were 
expressed as percentage of counts retained in the stomach (percent gastric 
retention) over time. Results: There were no side effects of erythromycin. In the 
placebo group, the mean percent of radiolabeled meal retained in the stomach 
after 90 minutes was 88%, which was significantly greater than in the 
erythromycin group, 37% (p < 0.001). In addition, analysis of covariance 
demonstrated that the rate of gastric emptying (slope of the line) was 
significantly greater in the erythromycin-treated group than in the placebo 
group (p < 0.0001). Conclusion: Early satiety after esophagogastrectomy ay 
be due to delayed gastric emptying and not due to a decrease in the gastric 
reservoir. Intravenous erythromycin significantly improves gastric emptying in 
patients after esophagogastrectomy by stimulating astric motility. (J TnORAC 
CARDIOVASC SURG 1996;111:649-54) 
D elayed gastric emptying after gastric, pancreatic, and esophageal operations is a common event, 
occurring in up to 50% of patients. 1-4 When clini- 
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cally significant, medical therapy is instituted, usu- 
ally with limited success. Metaclopramide, bethane- 
chol, domperidone, and cisapride have been studied 
in patients, with little success. 5-7 
Erythromycin, a motilin agonist, 8 has been dem- 
onstrated to improve gastric emptying in normal 
subjects, 9 patients with diabetic gastroparesis] ° and 
patients with postvagotomy gastroparesis. 11 
With these preliminary observations, we designed 
a prospective randomized trial to evaluate the effi- 
cacy of erythromycin in improving gastric emptying 
in human beings after esophagogastrectomy. 
Patients and methods 
From October 1990 to October 1992, 24 patients un- 
dergoing esophagogastrectomy and pyioric drainage were 
randomized to receive erythromycin ( = 13) or placebo 
(n = 11) just before a radionuclide gastric emptying study. 
All patients igned an informed consent form to partici- 
pate in this study, after having been approved by our 
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Table I. Demographics of the 24 patients 
randomized to receive rythromycin orplacebo 
Erythromycin Placebo p 
(n = 13) O~ = 11) Value 
Median age (yr) 64 66 NS 
Sex NS 
Male 11 7 
Female 2 4 
Histologic type NS 
Adenocarcinoma 7 6 
Squamous cell carcinoma 6 5 
Location of tumor NS 
Gastroesophageal junction 5 4 
Lower third of esophagus 6 3 
Middle third of esophagus 2 2 
Upper third of esophagus 0 2 
Operation NS 
Ivor Lewis 10 7 
Transhiatal 0 3 
Thoracoabdominal 2 0 
Transabdominal 1 1 
Drainage procedure NS 
Pyloromyectomy 9 3 
Pyloromyotomy 3 6 
Pyloroplasty 1 2 
NS, Not significant. 
institutional review board. All patients underwent a
barium swallow on days 6 to 8 to ensure that the 
esophagogastrostomy was intact. Patients were started 
by receiving liquids and advanced to solid foods by 
days 10 or 11. On the eleventh postoperative day, 
after an overnight fast, the patients received an intra- 
venous infusion of erythromycin lactobionate (200 mg 
in 50 ml normal saline solution) over 15 minutes, or else 
placebo (50 ml normal saline solution). After infusion 
of the erythromycin or placebo, patients ingested a 
standardized meal consisting of one scrambled egg 
labeled with 500 ~Ci of technetium 99m sulfur colloid, 
a slice of white bread, and 150 ml of water in 10 to 15 
minutes. 
Immediately after finishing their meal, the patients 
were positioned supine under an ADAC Genesys gamma 
camera (Milpetas, Calif.) equipped with a low-energy, 
all-purpose collimator and linked to a dedicated computer 
system. Dynamic images of the anterior part of the chest 
and upper part of the abdomen were then acquired every 
1 minute for 90 minutes. Regions of interest were then 
manually drawn around the gastric reminant, and derived 
time-activity curves were corrected for technetium decay. 
Results were expressed as the percentage of solid meal 
remaining in the stomach over time after completion of 
the meal. 
Data are presented as mean _+ standard deviation. 
Frequency data were analyzed by )(2 analysis, means by 
unpaired t test, and rate of gastric emptying by analyses of 
covariance. Significance was defined as p < 0.05. 
Results 
Twenty-four patients were studied after random- 
ization to erythromycin (n = 13) or placebo (n = 
11). They included 18 men and six women whose 
ages ranged from 41 to 79 years (median 66 years). 
Thirteen patients had adenocarcinoma and 11 had 
squamous cell carcinoma. The carcinoma was lo- 
cated in the gastroesophageal junction in nine, lower 
third of the esophagus in nine, middle third in four, 
and upper third in two. The operation performed 
was a standard Ivor Lewis resection in 17, transhia- 
tal in three, left thoracoabdominal in two, and 
transabdominal in two. All 24 patients underwent a 
drainage procedure: pyloromyectomy in 12, pyloro- 
myotomy in nine, and pyloroplasty in three. Table I 
shows that there were no significant differences in 
the aforementioned parameters in the two groups of 
patients. 
No adverse side effects resulted from either the 
erythromycin fusion or the gastric emptying study. 
Fig. 1 depicts the percentage of solid meal re- 
tained in both groups over the 90-minute study 
period. As noted, the group receiving erythromycin 
had a significant increase in gastric emptying. At 
90 minutes, the erythromycin group retained 
37% _+ 27% of the meal, which was significantly less 
than the 88% _+17% retained by the placebo group 
(p < 0.0001). Analysis of covariance demonstrated 
that the rate of gastric emptying (slope of the line) 
was significantly greater in the erythromycin-treated 
group than in the placebo group (p < 0.0001). 
Discussion 
This study suggests that patients have a delay in 
gastric emptying after esophagogastrectomy. When 
these patients ingest a radiolabled meal, approxi- 
mately 88% is retained in the stomach at 90 minutes. 
In contrast, when healthy volunteers ingest a radio- 
labeled meal, only 20% to 40% is retained, a2' 13 
Many patients experience "early satiety" after 
esophagectomy, and this has been attributed to the 
small capacity of the esophageal substitute, or to 
loss of the gastric reservoir function. 4 This study 
suggests that early satiety may be due to a marked 
delay in gastric emptying in patients undergoing 
esophagectomy, at least in the early postoperative 
period. 
Various agents have been evaluated to promote 
gastric emptying, such as metaclopramide, bethane- 
chol, domperidone, and cisapride, but none has 
been found satisfactory. 5-7 Erythromycin, on the 
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Fig. 1. Results of gastric emptying study. At 90 minutes, patients receiving erythromycin had significantly 
less radionuclide meal retained in the stomach (37%) than those receiving placebo (88%) (p < 0.0001). 
gastric emptying in patients with diabetic gastropa- 
resis.lO, 14 It has subsequently been shown to in- 
crease gastric emptying in other medical causes of 
gastroparesis, uch as scleroderma, 15 anorexia ner- 
vosa, 16 cirrhosis, 17 and idiopathic disorders. 17 
Erythromycin appears to promote gastric motility 
and subsequent emptying by acting as a motilin 
agonist. 8 In vitro studies of smooth muscle demon- 
strate that contraction curves timulated by erythro- 
mycin mimic those of motilin, is' 19 Erythromycin, 
like other fourteen-member macrolides, competes 
with motilin for the motilin receptor on gastrointes- 
tinal smooth muscle and therefore probably acts as 
a motilin agonist. 2° In human beings, motilin recep- 
tors have been found in the smooth muscle of the 
gastric antrum and duodenum, z~ Evidence exists 
that physiologic doses of motilin stimulate interdi- 
gestive motility by inducing rhythmic phase 3 motor 
activity of the migrating motor complex, beginning 
in the gastric smooth muscle and migrating distally 
through the small bowel. 22-a4 Erythromycin has an 
almost idemical effect on interdigestive motility. 9' a5-27 
The role of erythromycin the therapy of surgi- 
cally induced gastroparesis of the upper gastrointes- 
tinal tract is undergoing investigation. Erythromycin 
by intravenous infusion significantly increased gas- 
tric emptying in dogs after vagotomy and Roux-Y 
antrectomy. 2s Similar results were later documented 
in human beings after truncal vagotomy and pyloro- 
plasty, 29 partial gastrectomy, 3° and truncal vagot- 
omy and antrectomy. 31 
In a large trial from The Johns Hopkins Hospital, 
patients undergoing partial or total pancreatectomy 
(with distal gastrectomy or a pylorus-sparing proce- 
dure) were randomized to intravenous erythromycin 
(200 mg every 6 hours) or placebo from postopera- 
tive days 3 to 10. The investigators found a signifi- 
cant increase in gastric emptying in the erythromy- 
cin-treated group compared with the control 
group. 32 
Because sophagectomy entails truncal vagotomy, 
delayed gastric emptying is a relatively common 
event, but in most patients it is a relatively minor 
clinical problem. However, clinically significant de- 
layed gastric emptying is noted in 4% to 6% of 
patients after esophagogastrectomy, 333s with no dif- 
ference between transthoracic and transhiatal tech- 
niques. Patients with a marked delay in gastric 
emptying may be severely debilitated. To date, no 
drugs have significantly relieved the problem of 
delayed gastric emptying after esophagogastrec- 
tomy. 
In this study, we document that delayed gastric 
emptying is uniformly present in the early postop- 
erative period after esophagectomy. We also show 
that intravenous erythromycin increases gastric 
emptying to the normal range. Whether these ini- 
tially encouraging results translate into decreasing 
postoperative r covery time and length of hospital 
stay, while improving nutritional status and quality 
of life, remains to be answered by carefully de- 
signed, prospective studies. 
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Another important area to be explored is the use 
of oral erythromycin in the outpatient setting for 
patients with chronic gastroparesis after esophagec- 
tomy. For most patients, gastric emptying is de- 
creased in the supine position and increased in the 
sitting or upright position for 3 to 12 months after 
esophagogastrectomyY -3s Still, some patients have 
chronic gastroparesis after esophagectomy99 
Mozwecz and associates 11 described a patient 
with chronic gastroparesis after esophagogastrec- 
tomy who had a marked increase in gastric emptying 
after 2 weeks of oral erythromycin therapy (250 mg 
before each meal and at bedtime). 11 This patient 
also had substantial essening of symptoms. Hill and 
associates 4°studied patients 3 months after esopha- 
gogastrectomy. One group received cisapride (10 
mg orally three times a day) and another erythro- 
mycin (250 mg orally three times a day) for 3 days. 
The control group received no therapy. After the 
treatment period they performed a gastric emptying 
radionuclide study. At 4 hours the control group 
retained 56% of the ingested meal, the cisapride 
group 50%, and the erythromycin group 18%. The 
authors concluded that oral erythromycin signifi- 
cantly increased gastric emptying in patients 3 
months after esophagogastrectomy. 
Although short-term use (4 weeks) of oral eryth- 
romycin has been beneficial in diabetic gastropare- 
sis, 1° it remains to be seen whether long-term use 
will benefit patients with medical or surgical gastro- 
paresis. The ideal drug for patients with chronic 
gastroparesis would have the following characteris- 
tics; (1) can be taken orally; (2) is long acting; (3) 
has no side effects; (4) will not cause tachyphylaxis, 
and (5) effectively increases gastric emptying to the 
normal range. 
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Discuss ion  
Dr. J. Kent TrinMe (San Antonio, Tex.). Dr. Burt, I 
would like to start out with one question. On several 
occasions I have encountered an atonic stomach after 
either a heart-lung or a bilateral lung transplant inwhich 
apparently I have either injured or cauterized both vagus 
nerves. Would erythromycin work in that situation? I 
remember one case in particular in which we tried every 
herb and unguent known to man and nothing worked. 
Dr. Burt. Dr. Trinkle, to date there are very few clinical 
studies addressing your question. Erythromycin has been 
shown to promote gastric emptying after pancreatoduo- 
denectomies in a randomized trial from The Johns Hop- 
kins Hospital. It has been shown to promote gastric 
emptying after vagotomy and antrectomy. I would think 
that erythromycin would work in your patients if the 
gastroparesis is due to the vagi being injured. 
Dr. Nasser Altorki (New York, N.Y.). Have you done 
any dose-response tudies to determine how much eryth- 
romycin you need to give? I noticed you gave it intrave- 
nously. Is there a correlation between the blood levels 
after intravenous and oral administration? Finally, can 
you reflect on the possible mechanism of action? 
Dr. Burr. Dr. Altorki, the mechanism of action is well 
documented. Erythromycin simulates the motilin receptor 
in the gastric antrum, leading to increased gastric empty- 
ing. 
Regarding pharmacokinetics, we have no data, any nor 
have I found any study to document blood levels of 
erythromycin versus gastric emptying. 
Erythromycin is effective orally. Hill and associates 
from Dublin have treated a group of patients after 
esophagogastrectomy, a standard Ivor Lewis procedure. 
They have shown that if you treat a patient for 3 days with 
250 mg orally, three times a day, gastric emptying will be 
markedly increased. 
Dr. Mark K. Ferguson (Chicago, Ill.). I would like to 
express a couple of concerns. The first is in regard to the 
mix of gastric emptying procedures between the two 
groups and whether this might have had some effect on 
the emptying studies that you performed. Second, if the 
emptying is so poor in the control group, maybe you could 
explain to me the value of any of the emptying procedures. 
Finally, could you speculate as to the utility of oral doses 
of erythromycin the acute period, and particularly on 
the absorption of erythromycin those patients? 
Dr. Burt. Regarding the different procedures, obviously 
these patients underwent esophagogastrectomy by the 
technique of choice of the surgeon and then entered the 
study. I had no control over the procedure done. How- 
ever, there is no significant difference between the groups 
with regard to the procedure used. 
This study was purposely done supine. Other published 
studies evaluated posture, emptying in the sitting or 
upright position 3months to 12 months after operation. In 
these studies, gastric emptying is faster in patients who 
have had esophagectomy than in normal control subjects 
in the upright position but slower in the supine position. 
This study was done in the supine position to see if the 
stomach could maintain peristalsis. Obviously, the stom- 
ach has little peristalsis when the vagi are cut; it needs a 
stimulant, and erythromycin is a very effective stimulant of 
gastric emptying in this situation. Erythromycin has been 
used anecdotally, atour institution and others, in patients 
in whom decreased gastric emptying has become aclinical 
problem (4% to 6%). Erythromycin seems to allow these 
patients' stomachs to empty better so that they can go 
home instead of staying in the hospital until the stomach 
finally empties pontaneously. 
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Erythromycin does work orally. It is absorbed in the 
small bowel, so it becomes a problem in these patients 
because it has to get into the small bowel. If a patient has 
a clinically significant paresis, we start with erythromycin 
intravenously and then switch to oral erythromycin. 
Dr. Arthur N. Thomas (San Francisco, Calif.). We all 
know about the short elficacy of erythromycin from an 
antimicrobial aspect in the development of resistance. 
Obviously you are not going to use it in a long-term 
situation because of the danger of resistant organisms 
developing. I accept what you said for short-term use, but 
I am curious about whether the motility has had any 
permanent change from this regimen months later. 
Dr. Burt. Dr. Thomas, I personally have no data to 
address your question. There are data in patients with 
diabetic gastroparesis demonstrating that erythromycin 
given orally maintained its effect for 4 weeks. I know of no 
study following patients longer than that. 
As far as the antibiotic effect, there are companies and 
institutions looking at developing a motilin stimulant 
structurally similar to erythromycin, but without its anti- 
biotic properties. 
